
GLP-1 Weight-Loss Drugs Show Promising Eye Health Benefit in Seniors
A study of more than 157,000 obese adults without diabetes found GLP-1 receptor agonists (used for weight loss) are linked to an about 18% lower risk of developing age-related macular degeneration (AMD), rising to around 30% in unspecified AMD cases. The protective effect may stem from weight loss reducing systemic inflammation and oxidative stress, but the study is observational and short–term, so it cannot establish causation or mechanism. More research is needed to determine whether GLP-1s offer retinal protection or if weight loss itself drives the benefit.













